Skip to content
Font Size

Biologic Drug for Early RA?

Study: Adding an Anti-TNF Biologic Drug May Help When Methotrexate Isn't Enough
By
WebMD Health News
Reviewed by Louise Chang, MD

Aug. 6, 2009 -- In a new study, rheumatoid arthritis researchers say they've found a good plan for treating rheumatoid arthritis in its early stages. 

The study, published in The Lancet, included 487 adults in Sweden who had had rheumatoid arthritis (RA) for less than one year.

First, all of the patients took the drug methotrexate for three to four months. That was all that 145 patients -- about 30% -- needed to bring their rheumatoid arthritis symptoms to a low level.

The remaining patients continued taking methotrexate. Half of them also started taking two more pills  -- sulfasalazine and hydroxychloroquine -- to treat their RA.

The other half added a biologic drug called Remicade, which is given intravenously. Remicade belongs to a class of drugs called tumor necrosis factor (TNF) inhibitors.

One year later, 39% of the patients taking methotrexate plus Remicade had only low levels of RA symptoms, compared to 25% of patients taking methotrexate plus sulfasalazine and hydroxychloroquine.

The difference between the two groups didn't happen right away; the Remicade-plus-methotrexate group took the lead after six months of treatment, note the researchers, who included R.F. van Vollenhoven, MD, of the rheumatology clinic at Sweden's Karolinska University Hospital.

Adverse events were "balanced fairly well between the two groups" and were in line with the drugs' known side effects, van Vollenhoven and colleagues note.

The researchers aren't recommending anti-TNF drugs for everyone with RA, because anti-TNF drugs are more expensive than conventional drugs and aren't always needed or appropriate.

The researchers are following the patients for a second year; those results haven't been published yet.

"The results provide further evidence of the value of biological agents," states an editorial published with the study. Aggressive treatment, with a goal of remission, is also important, note the editorialists, who included Tuulikki Sokka, MD, PhD, of Finland's Jyvaskyla Central Hospital.

The study didn't compare Remicade to other anti-TNF drugs. It was funded in part by Schering-Plough, the drug company that markets Remicade outside the U.S.

Today on WebMD

rubbing hands
Avoid these 6 common mistakes.
woman roasting vegetables in oven
Four that fight inflammation.
 
mature woman threading needle
How much do you know about these RA myths and facts?
Patients who take the product would get no
This may lead to worsening symptoms.
 
Lucille Ball
Slideshow
Hand bones X-ray
Article
 
prescription pills
Article
Woman massaging her neck
Quiz
 
woman roasting vegetables in oven
Slideshow
Woman rubbing shoulder
Slideshow
 
Working out with light weights
Video
arthritis
Article